New acute myeloid leukemia-derived cell line: MUTZ-8 with 5q−

Abstract

The advent of continuous human leukemia-lymphoma cell lines as a rich resource of abundant, accessible and manipulable living cells has contributed significantly to a better understanding of the pathophysiology of hematopoietic tumors. We describe the establishment of the new continuous leukemia cell line MUTZ-8 from a patient with acute myeloid leukemia (AML): MUTZ-8 was derived from the peripheral blood of a 63-year-old woman with AML M4 (25 years after onset of myelodysplastic syndromes, MDS). DNA fingerprinting confirmed authenticity and derivation of the cell line. The immunoprofiling as determined by flow cytometry showed that MUTZ-8 is positive mainly for myeloid but also some monocytic and megakaryocytic markers, whereas it is negative for T cell, B cell and erythroid markers. The cell line is constitutively cytokine-dependent, proliferation requiring externally added cytokines. The cytokine response profiles showed a two-to 10-fold growth stimulation of the cells by various cytokines, whereas other cytokines led to growth inhibition. Cytogenetic analysis confirmed the common clonal derivation of the cell line and the malignant clone predominating at the times of sampling. MUTZ-8 displays a deletion of the 5q31 AML/MDS region effected by a non-reciprocal translocation, t(5;11)(q21;q10). The scientific utility of MUTZ-8 lies (1) in its cluster of pathognomonic cytogenetic alterations including a 5q31 breakpoint and (2) in its absolute cytokine dependency and proliferative response to various cytokines.

JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders

“…Cell lines were tested for JAK2 V617F expression applying the PCR-based ARMS system, a method that specifically amplifies the normal and mutant sequences plus a positive control band in a single reaction. 5 According to ARMS and direct sequencing of genomic PCR products, 5/79 cell lines carried the JAK2 V617F mutation (Figure 1a and b): MB-02 derived from a patient with a history of IM and myeloid metaplasia that developed into AML M7; 14 MUTZ-8 established from a patient with AML M4 25 years after the onset of MDS; 18 SET-2 from a patient at the stage JAK2 V617F mutation in cell lines H Quentmeier et al of leukemic transformation of ET; 19 and UKE-1 from a patient with ET, which transformed into acute leukemia. 20 The AML M6-derived cell line HEL was the only JAK2 V617F positive cell line tested lacking a known patient-history of MPD or MDS.…”

SOCS2: inhibitor of JAK2V617F-mediated signal transduction

“…Cell lines MB-02, 15 MUTZ-8, 16 SKNO-1 17 and UKE-1 18 were generously provided by the original investigators. The cell lines were cultivated according to the protocols described earlier.…”

Jiyuan oridonin A induces differentiation of acute myeloid leukemia cells including leukemic stem-like cells

“…Kasumi-1 (the M2 subtype of AML with t(8;21) translocation, DSMZ: ACC 220), KG-1 (leukemic stem-like cells established from the bone marrow cells of an AML patient, characterization of 98% CD34 + cells, DSMZ: ACC 14), MUTZ-8 (leukemic stem-like cells, characterization of 84% CD34 + cells, ACC 689) ( Hu et al, 2002 ), NB4 (M3 subtype of AML, APL cell line, DSMZ: ACC 207), and HL-60 (the M2 subtype of AML, ACC 3) cell lines were used. Cord blood samples from three healthy individuals (obtained from the Affiliated Hospital of Weifang Medical University, Weifang, China) were collected after obtaining written informed consent from the donors.…”